Diagnos Inc V.ADK

Alternate Symbol(s): DGNOF

Technology Information Technology Services

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.

TSXV:ADK - Post by User

Diagnos Inc

Bullboard Posts

Comment by u2bobon Apr 11, 2018 11:10am

85 Views

Post# 27866362

RE:Proof of concept

Conradsparrow wrote: There AI and proprietary software etc is this company’s value. Pharmacy companies don’t form partners etc with anyone... Adk will be bought out soon enough

Well if they do get bought out lets hope its not a 30 % premium : (

On the other hand we are dealing with at least 3 different named Pharma companies : )

And I like this one of the 3 we know of the new CEO is looking at AI in a big way ...

Novartis

On the commercial side, Novartis has been quite innovative in using digital media. Its heavily digital campaign for Gilenya, for example, won multiple awards. But until recently, it made relatively few big moves with artificial intelligence. This began to change with incoming CEO Vas Narasimhan. He announced in a September 2017 interview that he planned to partner with or acquire AI and data analytics companies. In January 2018, an article revealed that Novartis partnered with McKinsey’s QuantumBlack to analyze clinical trial operations with machine learning. They claim the work has reduced patient enrolment times by 10-15%. A March 2018 report also describes a partnership with IBM Watson to improve clinical trial recruitment, and the use of a “digital cortex” to predict medication efficacy.
https://blog.benchsci.com/pharma-companies-using-artificial-intelligence-in-drug-discovery